The 28-year-old heiress was expected to work at one of SK’s flagship units such as SK Innovation or SK Telecom. She reportedly decided to join the pharma unit as she has studied biological sciences at the University of Chicago.
After graduation in 2010, she worked at research centers in the US and then at a pharma firm in Korea. More recently, she worked for US consulting firm Bain & Company until January.
SK Group, the nation’s third-largest conglomerate in Korea, is pushing its pharma business that specializes in drugs for the central nervous system.
By Song Seung-hyun (email@example.com)